- Scheme Category:
- Equity Scheme >
- Sectoral/Thematic Funds
NAV: ₹ ↑ 2.2%
NAV chart
SMA (Simple Moving Average)
- 50 SMA
- 100 SMA
- 200 SMA
- 400 SMA
Returns
CAGR returns till date
CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option and its peers as on 6 May, 2026| Name | YTD | 1D | 1W | 1M | 3M | 1Y | 3Y | 5Y | 7Y | 10Y |
|---|---|---|---|---|---|---|---|---|---|---|
| Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option | 5.26% | 2.2% | 3.31% | 10.04% | 7.93% | 9.49% | 24.71% | 14.55% | 20.89% | 15.97% |
| SBI CONSUMPTION OPPORTUNITIES FUND - DIRECT PLAN - GROWTH | -4.16% | 0.71% | 0.2% | 7.63% | -0.15% | -2.63% | 12.57% | 16.83% | 15.57% | 16% |
| SBI ESG Exclusionary Strategy Fund - Direct Plan -Growth | -4.79% | 1.29% | 0.8% | 7.64% | -3.08% | 3.05% | 13.02% | 12.21% | 13.05% | 13.31% |
| SBI HEALTHCARE OPPORTUNITIES FUND - DIRECT PLAN -GROWTH | 8.33% | 1.61% | 3.72% | 10.83% | 10.77% | 9.26% | 27.44% | 17.03% | 22.34% | 13.99% |
| SBI INFRASTRUCTURE FUND - DIRECT PLAN - GROWTH | 3.7% | 0.3% | 0.59% | 14.47% | 4.83% | 9.37% | 21.99% | 21.72% | 19.97% | 16.9% |
| SBI PSU Fund - DIRECT PLAN - GROWTH | 7.09% | 1.05% | -0.19% | 7.83% | 2.87% | 21.25% | 32.17% | 27.94% | 21.02% | 17.03% |
Discrete returns (yearly)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | -9.42% | 8.09% | 4.71% | 2.97% | 68.53% | 23.84% | -9.16% | 41.33% | 35.46% | -2.94% |
Discrete returns (monthly)
| Month | Jul 2025 | Aug 2025 | Sep 2025 | Oct 2025 | Nov 2025 | Dec 2025 | Jan 2026 | Feb 2026 | Mar 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Returns | 2.66% | -1.41% | -2.52% | 2.24% | 0.9% | -1.24% | -4.66% | 5.31% | -4.85% | 6.03% |
Returns from spefic dates
| Description | CAGR returns from 18 Oct 2021 (Nifty 50 2021 high) | CAGR returns from 26 Sep 2024 (Nifty 50 2024 high) |
|---|---|---|
| Returns | 13.72% | 2.51% |
Portfolio
Asset allocation
| Equity | Debt | Realestate | Commodities | Cash & Equivalents |
|---|---|---|---|---|
| 99.45% | 0.00% (Arbitrage: 0.00%) | 0.00% | 0.00% | 0.55% |
Equity
| Name | Symbol / ISIN | Sector | Weight % |
|---|---|---|---|
| Sun Pharmaceutical Industries Limited | SUNPHARMA (INE044A01036) | Pharmaceuticals & Biotechnology | 13.92% |
| Lupin Limited | LUPIN (INE326A01037) | Pharmaceuticals & Biotechnology | 8.45% |
| Divi's Laboratories Limited | DIVISLAB (INE361B01024) | Pharmaceuticals & Biotechnology | 6.41% |
| Dr. Reddy's Laboratories Limited | DRREDDY (INE089A01031) | Pharmaceuticals & Biotechnology | 5.96% |
| Cipla Limited | CIPLA (INE059A01026) | Pharmaceuticals & Biotechnology | 5.42% |
| Apollo Hospitals Enterprise Limited | APOLLOHOSP (INE437A01024) | Healthcare Services | 5.15% |
| MedPlus Health Services Limited | MEDPLUS (INE804L01022) | Retailing | 3.86% |
| Ajanta Pharma Limited | AJANTPHARM (INE031B01049) | Pharmaceuticals & Biotechnology | 3.36% |
| Max Healthcare Institute Limited | MAXHEALTH (INE027H01010) | Healthcare Services | 3.24% |
| Vijaya Diagnostic Centre Limited | VIJAYA (INE043W01024) | Healthcare Services | 3.15% |
| Sai Life Sciences Limited | SAILIFE (INE570L01029) | Pharmaceuticals & Biotechnology | 3.15% |
| Mankind Pharma Limited | MANKIND (INE634S01028) | Pharmaceuticals & Biotechnology | 2.87% |
| Aurobindo Pharma Limited | AUROPHARMA (INE406A01037) | Pharmaceuticals & Biotechnology | 2.81% |
| IPCA Laboratories Limited | IPCALAB (INE571A01038) | Pharmaceuticals & Biotechnology | 2.77% |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO (INE159A01016) | Pharmaceuticals & Biotechnology | 2.64% |
| Abbott India Limited | ABBOTINDIA (INE358A01014) | Pharmaceuticals & Biotechnology | 2.43% |
| Alkem Laboratories Limited | ALKEM (INE540L01014) | Pharmaceuticals & Biotechnology | 2.17% |
| JB Chemicals & Pharmaceuticals Limited | JBCHEPHARM (INE572A01036) | Pharmaceuticals & Biotechnology | 2.09% |
| Dr. Lal Path Labs Limited | LALPATHLAB (INE600L01024) | Healthcare Services | 2.02% |
| Thyrocare Technologies Limited | THYROCARE (INE594H01019) | Healthcare Services | 1.94% |
| Pfizer Limited | PFIZER (INE182A01018) | Pharmaceuticals & Biotechnology | 1.90% |
| Gland Pharma Limited | GLAND (INE068V01023) | Pharmaceuticals & Biotechnology | 1.72% |
| Narayana Hrudayalaya Limited | NH (INE410P01011) | Healthcare Services | 1.67% |
| Emcure Pharmaceuticals Limited | EMCURE (INE168P01015) | Pharmaceuticals & Biotechnology | 1.51% |
| Sanofi Consumer Healthcare India Limited | SANOFICONR (INE0UOS01011) | Pharmaceuticals & Biotechnology | 1.16% |
| Suraksha Diagnostic Limited | SURAKSHA (INE877V01027) | Healthcare Services | 1.12% |
| Fortis Healthcare Limited | FORTIS (INE061F01013) | Healthcare Services | 1.11% |
| Sanofi India Limited | SANOFI (INE058A01010) | Pharmaceuticals & Biotechnology | 0.94% |
| Syngene International Limited | SYNGENE (INE398R01022) | Healthcare Services | 0.93% |
| Akums Drugs and Pharmaceuticals Limited | AKUMS (INE09XN01023) | Pharmaceuticals & Biotechnology | 0.89% |
| Anthem Biosciences Limited | ANTHEM (INE0CZ201020) | Pharmaceuticals & Biotechnology | 0.88% |
| Biocon Limited | BIOCON (INE376G01013) | Pharmaceuticals & Biotechnology | 0.67% |
| AstraZeneca Pharma India Limited | ASTRAZEN (INE203A01020) | Pharmaceuticals & Biotechnology | 0.62% |
| Indoco Remedies Limited | INDOCO (INE873D01024) | Pharmaceuticals & Biotechnology | 0.38% |
| Concord Biotech Limited | CONCORDBIO (INE338H01029) | Pharmaceuticals & Biotechnology | 0.14% |
Portfolio data is as on date 31 March, 2026
NAV history
Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option - 30 days NAV (Net asset value) history
| Date | NAV | % change |
|---|---|---|
| 6 May, 2026 | 599.4765 | 2.2% |
| 5 May, 2026 | 586.5475 | -0.13% |
| 4 May, 2026 | 587.3048 | 1.26% |
| 30 April, 2026 | 579.9839 | -0.05% |
| 29 April, 2026 | 580.2930 | 0.29% |
| 28 April, 2026 | 578.6001 | -0.36% |
| 27 April, 2026 | 580.6636 | 2.11% |
| 24 April, 2026 | 568.6673 | -1.15% |
| 23 April, 2026 | 575.2846 | 1.39% |
| 22 April, 2026 | 567.4146 | 0.35% |
| 21 April, 2026 | 565.4599 | 0.18% |
| 20 April, 2026 | 564.4158 | -0.27% |
| 17 April, 2026 | 565.9347 | 0.32% |
| 16 April, 2026 | 564.1348 | -0.14% |
| 15 April, 2026 | 564.9044 | 1.41% |
| 13 April, 2026 | 557.0463 | -0.13% |
| 10 April, 2026 | 557.7510 | 0.65% |
| 9 April, 2026 | 554.1348 | 0.67% |
| 8 April, 2026 | 550.4254 | 0.79% |
| 7 April, 2026 | 546.0989 | 0.24% |
| 6 April, 2026 | 544.8019 | 0.15% |
| 2 April, 2026 | 543.9665 | -0.56% |
| 1 April, 2026 | 547.0158 | -0.35% |
| 31 March, 2026 | 548.9228 | 0% |
| 30 March, 2026 | 548.9359 | -1.18% |
| 27 March, 2026 | 555.4694 | -0.94% |
| 25 March, 2026 | 560.7225 | 1.58% |
| 24 March, 2026 | 552.0262 | 1.16% |
| 23 March, 2026 | 545.6965 | -2.02% |
| 20 March, 2026 | 556.9533 |
FAQ (Frequently asked questions)
What is latest/current NAV/price of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The latest NAV of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option is 599.4765 as on 6 May, 2026.What are YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The YTD (year to date) returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 5.26% as on 6 May, 2026.What are 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 1 year returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 9.49% as on 6 May, 2026.What are 3 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 3 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 24.71% as on 6 May, 2026.What are 5 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 5 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 14.55% as on 6 May, 2026.What are 10 year CAGR returns of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option?
The 10 year annualized returns (CAGR) of Nippon India Pharma Fund - Direct Plan Growth Plan - Growth Option are 14.55% as on 6 May, 2026.